文献速递生殖医学

人工周期中使用微粉化阴道黄体酮阴道栓剂或胶囊进行黄体期支持:是否存在差异?

Luteal phase support using micronized vaginal progesterone as pessaries or capsules in artificial cycles: is there any difference?
PubMed 文献 · Reprod Biomed Online · 2023-10-22

这项回顾性、匹配队列、单中心研究比较了激素替代治疗-胚胎移植周期中阴道栓剂(Cyclogest)与胶囊(Utrogestan、Progeffik)用于黄体期支持的差异。共分析2665个周期,栓剂组移植日血清孕酮均值更高,孕酮<8.8 ng/ml的比例更低,但两组妊娠结局无差异。

要点

  • 栓剂组移植日血清孕酮均值14.5±5.1 ng/ml,高于胶囊组的13.0±4.8 ng/ml(P=0.000)。
  • 栓剂组孕酮<8.8 ng/ml的比例为10.3%(95%CI 7.9-12.6%),低于胶囊组的17.9%(95%CI 16.2-19.6%)。
  • 两组妊娠结局无差异。

核心结论

  • 使用微粉化阴道黄体酮栓剂而非胶囊进行黄体期支持,可使胚胎移植日血清孕酮浓度不达标的患者显著减少,栓剂组需要补救治疗的患者几乎减少50%。

研究设计与样本

  • 回顾性、匹配队列、单中心研究,比较激素替代治疗-胚胎移植周期中阴道栓剂(Cyclogest)与胶囊(Utrogestan、Progeffik)用于黄体期支持。
  • 纳入年龄<50岁、子宫内膜三线征厚度≥6.5 mm、移植1或2个囊胚的患者。
  • 共分析2665个激素替代治疗-胚胎移植周期,其中663个(24.9%)使用栓剂,2002个(75.1%)使用胶囊。

主要发现

  • 移植日血清孕酮均值:栓剂组14.5±5.1 ng/ml,胶囊组13.0±4.8 ng/ml(P=0.000)。
  • 移植日血清孕酮<8.8 ng/ml的比例:栓剂组10.3%(95%CI 7.9-12.6%),胶囊组17.9%(95%CI 16.2-19.6%);校正比值比0.426(95%CI 0.290-0.625;P=0.000)。
  • 两组妊娠结局无差异。

临床怎么用

  • 移植日血清孕酮<8.8 ng/ml的患者接受单次皮下注射额外孕酮作为补救治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Is there a difference between the proportion of patients with serum progesterone <8.8 ng/ml on the day of embryo transfer when micronized vaginal progesterone (MVP) for luteal phase support (LPS) is given as pessaries versus capsules? DESIGN: This retrospective, matched-cohort, single-centre study compared pessaries (Cyclogest) versus capsules (Utrogestan, Progeffik) for LPS in hormone replacement treatment-embryo transfer (HRT-ET) cycles. Patients under 50 years old with a triple-layer endometrial thickness of ≥6.5 mm underwent transfer of one or two blastocysts. Serum progesterone concentrations were measured on the day of transfer; patients with concentrations <8.8 ng/ml received a single 'rescue' dose of additional progesterone by subcutaneous injection. RESULTS: In total 2665 HRT-ET cycles were analysed; 663 (24.9%) used pessaries for LPS and 2002 (75.1%) used capsules. Mean serum progesterone concentrations with standard deviations on the day of embryo transfer were significantly higher in the group using MVP pessaries compared with those using capsules (14.5 ± 5.1 versus 13.0 ± 4.8 ng/ml; P = 0.000). The percentage of participants with suboptimal serum progesterone concentrations on the day of embryo transfer (<8.8 ng/ml) was significantly lower in the pessary group than the capsule group (10.3%, 95% confidence interval [CI] 7.9-12.6% versus 17.9%, 95% CI 16.2-19.6%; adjusted odds ratio 0.426, 95% CI 0.290-0.625; P = 0.000). No differences in pregnancy outcome were observed between the groups. CONCLUSIONS: Using MVP pessaries rather than capsules for LPS resulted in significantly fewer patients having suboptimal serum progesterone concentrations on the day of embryo transfer. Consequently, almost 50% fewer patients in the pessary group needed rescue treatment.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Labarta E, Rodríguez-Varela C, Salvaleda-Mateu M, et al. Luteal phase support using micronized vaginal progesterone as pessaries or capsules in artificial cycles: is there any difference? Reprod Biomed Online. 2023. PMID: 38484430. doi:10.1016/j.rbmo.2023.103638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。